Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
BRANFORD, Conn., Jan. 21, 2016 -- BioXcel Corporation, a global leader in cloud-based big data platforms and developer of transformative patient treatments, today announced the launch of its first in class PharmGPS® Oncology and Immuno-Oncology Suite. The platform’s comprehensive big data approach provides industry stakeholders with actionable intelligence to empower the selection, prioritization, identification and development of promising immunotherapies across the broad oncology spectrum.
“We have reached an exciting inflection point in our integrated discovery ecosystem where the application of our big data technology enables the identification of therapeutic candidates with the highest probability of success to create tangible value for our partners and potentially change the cancer treatment paradigm,” said BioXcel’s President and Chief Scientific Officer, Krishnan Nandabalan, Ph.D. “This platform is designed to overcome the key challenges faced by oncologists and patients by creating potentially disruptive therapies in a rational and highly efficient manner.”
With the PharmGPS® Oncology and Immuno-Oncology Suite, partners are able to optimize their portfolios and pipeline assets by identifying and prioritizing mono- and combination therapies that have the greatest potential to improve patient outcomes for specific tumor types. The Oncology and Immuno-Oncology suite currently spans over 40 different tumors, 484 unique drugs and combinations, 115 validated drugs and novel targets along with multiple modalities including targeted therapies, immunotherapies, vaccines and cellular therapies. The user-friendly interface allows for an in-depth overview of the immuno-oncology landscape, target-drug-pathway-indication networks and scenario analyses of potential therapeutic outcomes using immunotherapies in cancer.
"Our first-of-its-kind big data analytics platform is integrating and expanding upon decades of knowledge in the oncology space to drive therapeutic innovation and improve patient outcomes. We believe that PharmGPS® Oncology and Immuno-Oncology Suite has the potential to become an indispensable tool for our biopharma customers and partners, and a critical asset for BioXcel as we build our own portfolio of oncology assets,” said BioXcel’s Vice President, Oncology R&D, Luca Rastelli, Ph.D.
The company will be showcasing its platform at Phacilitate's Immunotherapy World Forum conference in Washington D.C on January 25th- 27th.
PharmGPS® Oncology and Immuno-Oncology Suite
A live and multi-dimensional platform, BioXcel's proprietary suite enables the extensive analysis of tumors and the impact of constituent global drug pipelines and benchmarking, novel drug targets and therapeutic approaches, including the inhibition of immune checkpoints, on standards of care and lines of therapies. All key drivers necessary for designing the most optimal combination therapies, clinical trial design and positioning of the right anti-cancer agents are taken into account to maximize market share and most importantly benefit to the patient. Furthermore, the suite is comprehensive in assessing all modalities, combinations of therapies and different stages of development. This extensive analysis delineates an optimal path with respect to indication segment relevance, best-fit therapies, and target effectiveness compared to the most relevant standard of care.
About BioXcel
BioXcel is a global leader in providing cloud-based Pharma big data solutions for discovering novel products and performance benchmarking of pipeline innovation and marketed products in all major therapeutic areas. Our first in class Big Data Innovation Lab is focused on the development of transformative patient treatments for strategic portfolio growth and leverages; PharmGPS® - a live analytics platform; an Integrated Center of Xcellence housing multidisciplinary scientific, commercial and medical teams; and a drug development team that offers deep domain expertise. Committed to innovation, product excellence and partner success, BioXcel's global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA with operations in Asia.
CONTACT: BioXcel Corporation Anita Ganjoo Corporate Communications Email: [email protected] Tel: 203 957 2487
